

Activation hypoxia inducible factor-1 α gene affected the tumor microenvironment and induced recurrence and invasion of bladder cancer *in vitro*

La activación del gen hypoxia inducible factor-1 α afectó el microambiente del tumor e indujo la recurrencia e invasión del cáncer de vejiga

Jiangang Chen^{1,2}, Lin Hao^{1,3}, Zhiguo Zhang^{1,3}, Shaoqi Zhang¹, Yong Zhang², Bingzheng Dong^{1,3}, Qianjin Zhang^{1,4}, and Conghui Han^{1,3*}

¹Department of Urology, The Third Affiliated Hospital of Soochow University; ²Department of Urology, The second affiliated hospital of Nantong University; ³Department of Urology, Xuzhou Central Hospital, Xuzhou; ⁴Department of Urology, The First People's Hospital of Suqian. Jiangsu, China

Abstract

Objective: This work aimed to investigate the molecular mechanism of the activation of hypoxia-inducible factors under different low oxygen partial pressures. **Methods:** Strictly follow in vitro aseptic culture of bladder cancer cell line UMUC3 and when the cells grow in the logarithmic phase, culture the cells under different low oxygen partial pressures. Among these groups, two groups of cells were transfected with small interfering-hypoxia inducible factor 1 α (si-HIF-1 α) liposome plasmids to silencing the HIF-1 α expression. **Results:** Cell cloning experiment showed that HIF-1 α will increase cell adhesion and proliferation under hypoxia. Matrigel angiogenesis experiment showed that hypoxia has a negative impact on the angiogenesis of tumor cells. Cell scratch test indicated that hypoxia has a greater impact on the migration ability of cancer cells, and HIF-1 α has a significant impact on the migration process. Cell invasion test proved that hypoxia has a greater impact on the invasion ability of cancer cells, and HIF-1 α has a great impact on the invasion process. **Conclusion:** HIF-1 α can target the regulatory gene vascular endothelial growth factor to promote tumor cell proliferation, migration, invasion, neovascularization and lymph node metastasis.

Keywords: Bladder cancer. Hypoxia inducible factor-1 α . Vascular endothelial growth factor.

Resumen

Objetivo: Por lo tanto, este trabajo investiga el mecanismo molecular de la activación de factores inducibles por hipoxia bajo diferentes presiones parciales de oxígeno bajas. **Métodos:** Siga estrictamente el cultivo aséptico in vitro de la línea celular de cáncer de vejiga UMUC3 y cuando las células crezcan en la fase logarítmica, cultive las células bajo diferentes presiones parciales de oxígeno bajas. Entre estos grupos, se transfirieron dos grupos de células con plásmidos de liposomas si-HIF-1 α para silenciar la expresión de HIF-1 α . **Resultados:** El experimento de clonación celular mostró que HIF-1 α aumentará la adhesión y proliferación celular bajo hipoxia. El experimento de angiogénesis de Matrigel mostró que la hipoxia tiene un impacto negativo en la angiogénesis de las células tumorales. La prueba de raspado celular indicó que la hipoxia tiene un mayor impacto en la capacidad de migración de las células cancerosas, y HIF-1 α tiene un impacto significativo en el proceso

*Correspondence:

Conghui Han

E-mail: chhan825@21cn.com

Date of reception: 12-01-2022

Date of acceptance: 12-07-2022

DOI: 10.24875/CIRUE.M22000544

Cir Cir (Eng). 2022;90(5):578-585

Contents available at PubMed

www.cirugiaycirujanos.com

2444-0507/© 2022 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

de migración. La prueba de invasión celular demostró que la hipoxia tiene un mayor impacto en la capacidad de invasión de las células cancerosas y HIF-1 α tiene un gran impacto en el proceso de invasión. **Conclusión:** HIF-1 α puede dirigirse al gen regulador vascular endothelial growth factor para promover la proliferación, migración, invasión, neovascularización y metástasis en los ganglios linfáticos de las células tumorales.

Palabras clave: Cáncer de vejiga. Hypoxia inducible factor-1 α . Vascular endothelial growth factor.

Introduction

Bladder cancer is a malignant tumor that occurs on the bladder mucosa. It is the most common malignant tumor of the urinary system and one of the ten most common tumors throughout the body^{1,2}. It accounts for the first place in the incidence of genitourinary tumors in our country, and its incidence is second only to prostate cancer in the West³. Bladder cancer is easy to recur, with the highest recurrence rate among solid tumors. After undergoing transurethral resection of bladder tumors, it requires regular reexaminations, and the recurrence rate of patients is as high as 50%⁴. It is precisely because of the high incidence and mortality of bladder cancer that the research on its mechanism has not stopped.

Hypoxia inducible factor-1 (HIF-1) was first discovered by Semenza and Wang in 1992, and the structure of HIF-1 was subsequently established and its cDNA coding sequence was proved⁵. HIF-1 is ubiquitous in human and mammalian cells. It can be stably expressed under hypoxic conditions, and is also expressed under normoxia. However, the synthesized HIF-1 protein is rapidly degraded through the intracellular oxygen-dependent ubiquitin protease degradation pathway⁶.

HIF-1 is a dimeric transcription factor composed of two protein subunits. It has a specific sensitivity to hypoxia, and its expression is tightly controlled by intracellular oxygen partial pressure. HIF-1 participates in the transcriptional regulation of many hypoxia-responsive genes in the body, and is a key factor in the body's hypoxia response⁷. HIF-1 plays a key role in the reprogramming of cancer metabolism by activating the transcription of genes encoding glucose transporters and glycolytic enzymes. Many metabolic abnormalities in cancer cells increase HIF-1 activity.

Vascular endothelial growth factor A (VEGFA) is secreted by tumor cells, macrophages and fibroblasts, and is widely distributed in many tissues of the human body, such as glands, lungs, liver, kidneys, and myocardium⁸. However, its expression level is extremely low, and its role is only to maintain normal blood

vessel density and Basic penetration function to maintain nutrients⁹. When tumor cells appear, their expression levels will generally rise greatly. Studies have shown that VEGFA is related to tumor invasiveness and tumor susceptibility. The structure of VEGFA protein is a homodimer composed of two peptide chains through disulfide bonds¹⁰. It is commonly found in the central nervous system, reproductive system and tumor tissues. Its main functions include electively enhance mitosis of vascular endothelial cells, stimulate endothelial cell proliferation, and promote blood vessel formation, increase the permeability of blood vessels, especially small blood vessels, and make plasma macromolecules extravasate and deposit in the extravascular matrix to provide nutrition for the growth of tumor cells and the establishment of new capillary network¹¹.

Through protein function analysis, it is found that HIF-1 α can target the regulatory gene VEGFA to promote tumor cell proliferation, migration, invasion, neovascularization, and lymph node metastasis.

This work aimed to investigate the molecular mechanism of the activation of hypoxia-inducible factors under different low oxygen partial pressures.

Materials and methods

Cell model construction

Cultivate the bladder cancer cell line UMUC3 in strict accordance with the requirements of *in vitro* aseptic culture, and then wait until the cells grow to the logarithmic phase. Place the cells in a Plexiglass box with volume fractions 5% CO₂/95% O₂, 5% CO₂/95% N₂, and 5% CO₂/5% O₂/90% N₂ and continue to culture for 30 min, naming normal control (NC), hypoxia group-1 (Hy-1), and hypoxia group-2 (Hy-2), respectively. At the same time, continue to culture two groups of cells in 5% CO₂/95% N₂, 5% CO₂/5% O₂/90% N₂ Plexiglass boxes, and transfect small interfering hypoxia-inducible factor 1 α (si-HIF-1 α) liposome plasmid, naming Hy-1 + si-HIF-1 α group, and Hy-2 + si-HIF-1 α group.

Cell scratch test

After the control group and the experimental group were digested and counted, 8×10^5 cells were divided into 35 mm² culture dishes. Use a marker to draw a line on the bottom of the dish as a mark, aspirate the culture medium, and use a 10 μ L pipette tip to mark the cells in the dish perpendicularly to the marker. Rinse with phosphate buffered saline (PBS) to remove the marked cells, add serum-free culture medium to continue culturing. Take pictures at 0 h and 24 h, and select the intersection of the line drawn by the marker and the cell scratch as the observation point, and then observe at a fixed point.

Cell cloning experiment

Take each group of cells in the logarithmic growth phase, digest them with 0.25% trypsin and pipette into single cells, and suspend the cells in a culture medium of 10% fetal bovine serum for later use. The cell suspension was diluted in gradient multiples, and each group of cells was inoculated into a dish containing 10 mL of pre-warmed culture medium at 37°C at a gradient density of 50, 100, and 200 cells per dish, and gently rotated to make the cells uniformly dispersed. Place it in a cell incubator at 37°C, 5% CO₂ and saturated humidity for 2-3 weeks. It is frequently observed that when there are visible clones in the Petri dish, stop the culture. The supernatant was discarded and washed carefully with PBS twice. Add 4% paraformaldehyde to fix the cells with 5 mL and fix for 15 min. Then remove the fixative solution, add appropriate amount of GIMSA and apply the dye solution to dye for 10-30 min, and then slowly wash off the dye solution with running water. Turn the plate upside down and superimpose a transparent film with a grid. Count the clones directly with the naked eye, or count the clones with more than 10 cells on a microscope (low power). Finally, the clone formation rate was calculated with the following equation.

$$\text{Clone formation rate} = \frac{\text{Number of clones}}{\text{Number of inoculated cells}} \times 100\%$$

Cell migration

Twenty-four hours before the experiment, the cells of different groups were replaced with serum-free medium, and the culture was continued. Before inoculation, soak

the 24-well plate and transwell chamber with 1 $\times$ PBS for 5 min to moisten the chamber. Digest the cells, wash the cells with serum-free medium, resuspended the cells in serum-free medium, count the cells and dilute to adjust the cell density to 5×10^5 /mL. Inoculate 0.2 mL cell suspension (5×10^4 cells) into the transwell chamber, and then add 0.7 mL of RPMI-1640 medium containing 10% FBS to the lower 24-well plate, 3 replicate holes per group, and place them in a 37°C incubator for 24 h to terminate the culture. Add 1 mL of 4% formaldehyde solution to each well of the above cells, and fix them at room temperature for 10 min. Aspirate the fixative solution, wash once with 1 $\times$ PBS. Add 1 mL 0.5% crystal violet solution to each well, wash with 1 $\times$ PBS three times after dyeing for 30 min. Use a cotton swab to carefully wipe off the cells that have not migrated in the transwell, place them under a 200 $\times$ microscope, and count the number of cells in each field of view.

Matrigel angiogenesis

Prepare matrigel and add it to the lower hole of the ibidi angiogenesis slide. Put the matrigel glue into the incubator to make it coagulate. Prepare a cell suspension with a density of 2×10^5 cells/mL, and add 50 μ L of the cell suspension to the solidified ibidi angiogenesis slide. According to the growth rate of the cells, images are collected periodically for observation.

Western blot analysis

Collect tumor cells from each group, and add 200 μ L of cell lysate to each six-well plate. After sonication, the cells were lysed on ice for 1 h. The lysed cell sample was centrifuged at 12,500 rpm for 15 min at 4°C. Then, transfer the supernatant in the centrifuge tube to a clean centrifuge tube. BCA protein quantification kit was used to quantify protein concentration. The measured protein samples were stored at -80°C. In Western blot electrophoresis, the protein loading concentration was 50 μ g per well. After SDS-PAGE electrophoresis, the membrane was transferred and blocked. HIF-1 α , VEGFA, and GAPDH (1: 500, anti-human, Abcam, USA) primary antibody were diluted to use concentration. The samples were incubated overnight on a shaker at 4°C. After washing with PBS, the samples were incubated with the secondary antibody (1: 1000, anti-human, Abcam, USA) for 30 min at room temperature in the dark. Finally, the developer was used for development and photography.




Figure 1. The results of cell cloning experiment. The result of normal control (NC) group is equivalent to that of healthy people. **A:** NC group. **B:** hypoxia group-1 (Hy-1) group. **C:** hypoxia group-2 (Hy-2) group. **D:** Hy-1 + small interfering hypoxia-inducible factor 1 α (si-HIF-1 α) group. **E:** Hy-2 + si-HIF-1 α group.

Statistical analysis

The experimental results are expressed as mean $\pm$ standard deviation. Statistical analysis was performed using SPSS 22.0 software. The figures were produced with Origin 2020 software.

Results

Cell cloning experiment

Only cells that have both adherent and proliferative viability can form clones. As can be seen from figure 1, compared to the NC group, the number of cell clones in the other four groups is significantly reduced. The trend of the number of cell clones in the four groups of the experimental group is that Hy-2 group is larger than Hy-1 group, which indicated that cell hypoxia will negatively affect cell adhesion and proliferation activity. Hy-1 group is larger than Hy-2 + si-HIF-1 α group, and Hy-1 + si-HIF-1 α group is the least one. This showed that under hypoxic conditions, the inhibition

of the expression of HIF-1 α will make the situation worse, indicating that HIF-1 α will increase cell adhesion and proliferation under hypoxia.

Matrigel angiogenesis experiment

Tumor cells themselves can secrete a variety of growth factors and induce angiogenesis. Angiogenesis plays an important role in the development and metastasis of tumors. The results shown in figure 2 demonstrated that the angiogenesis was obvious in the NC group, but not in the other groups. This shows that hypoxia has a negative impact on the angiogenesis of tumor cells. HIF-1 α also participates in the regulation of this process.

Cell scratch test

The cell scratch method is one of the simple and easy methods to detect the movement characteristics of tumor cells. It draws on the *in vitro* cell wound healing experimental model, *in vitro* cultured monolayer




Figure 2. The results of matrigel angiogenesis experiment. The result of normal control (NC) group is equivalent to that of healthy people. **A:** NC group. **B:** hypoxia group-1 (Hy-1) group. **C:** hypoxia group-2 (Hy-2) group. **D:** Hy-1 + si-HIF-1 α group. **E:** Hy-2 + si-HIF-1 α group.

cells, scratches and wounds, and then adds drugs or overexpression or interference with its gene expression to observe its ability to inhibit tumor cell migration. It is shown from figure 3 that the cancer cell migration ability of the NC group is relatively strong, while the other four experimental groups are relatively weak. But relatively speaking, the migration ability is that Hy-2 group is more evident than Hy-1 group, which indicated that the lower the oxygen partial pressure, the weaker the migration ability of cancer cells. Hy-1 group is better than Hy-2 + si-HIF-1 α group, and Hy-1 + si-HIF-1 α group is the weakest one. This shows that HIF-1 α gene will further inhibit the migration ability of cancer cells on the basis of low oxygen partial pressure.

Cell invasion test

The results of the transwell experiment are shown in figure 4. The NC group has strong invasive ability, while the other four groups have weak invasive ability. But for the remaining four groups, the tendency of invasion ability is that Hy-2 group is more evident than Hy-1 group, which showed that low partial pressure of oxygen reduces the invasion ability of cancer cells. Hy-1 group is better than Hy-2 + si-HIF-1 α group, and Hy-1 + si-HIF-1 α group is the weakest one. This indicated

that the presence of the HIF-1 α gene will further reduce the invasion ability of cancer cells on the basis of low oxygen partial pressure.

Western blot

Figure 5 shows the up-regulation of HIF-1 α expression in Hy-2 group and Hy-1 group relative to NC group. It can be seen that the hypoxic environment can cause the overexpression of HIF-1 α . The HIF-1 α expression of Hy-2 + si-HIF-1 α group and Hy-1 + si-HIF-1 α group was downregulated, indicating that the transfection of si-HIF-1 α effectively inhibited the expression of HIF-1 α . The results in figure 5 also show that, relative to the NC group, the expression of VEGFA in Hy-2 group and Hy-1 group also increased, in Hy-2 + si-HIF-1 α group, and Hy-1 + si-HIF-1 α group, the expression of VEGFA is significantly reduced. The trend of VEGFA is consistent with HIF-1 α , so HIF-1 α can target and regulate gene VEGFA to promote tumor cell proliferation, migration, invasion, and angiogenesis.

Discussion

Bladder cancer is a malignant tumor that occurs in the bladder mucosa. It is the most common malignant tumor of the urinary system and one of the ten most




Figure 3. The results of cell scratch test. The result of normal control group is equivalent to that of healthy people. In general, the cell scratch test does not do statistical analysis.

common tumors in the whole body. Symptoms include blood in the urine, painful urination and low back pain. The most common type of bladder cancer is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma¹². Diagnosis is usually made by cystoscopy with tissue biopsy. The stage of cancer depends on transurethral resection and medical imaging. Treatment depends on the stage of the cancer and may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy. Surgical options may include transurethral resection, partial or complete bladder removal, or catheterization¹³. Our experiment has proved that HIF-1 α gene can induce the recurrence and invasion of bladder cancer. Therefore, countermeasures to deal with HIF-1 α should be considered during treatment.

HIF-1 α is a subunit of the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1) encoded by the HIF1A gene. It is a basic helix-loop-helix PAS domain that contains proteins and is considered to be the main transcriptional regulator of the hypoxia response of cells and development. The dysregulation

and overexpression of HIF1A caused by hypoxia or genetic mutations is of great significance in cancer biology and many other pathophysiology, especially in angiogenesis and angiogenesis, energy metabolism, cell survival, and tumor invasion^{14,15}. Two other alternative transcripts encoding different isoforms have been identified. The response mechanism of HIF-1 α gene to intracellular oxygen partial pressure is still unclear, which can be a follow-up study of this project for more in-depth research.

VEGF-A is a dimeric glycoprotein that plays an important role in neurons and is considered to be the main and main inducer of blood vessel growth. VEGF-A is essential for adults in organ remodeling and diseases involving blood vessels (such as wound healing, tumor angiogenesis, diabetic retinopathy, and age-related macular degeneration). During early vertebrate development, angiogenesis occurs, which means that the endothelium condenses into blood vessels. The differentiation of endothelial cells depends on the expression of VEGFA, if this expression is eliminated, it may lead to embryonic death. The result of alternative splicing is VEGFA produced by a set of three main isoforms. If any three isoforms (VEGFA120, VEGFA164, and VEGFA188) are produced, then this will not cause vascular malformations and intact VEGFA in mice. The death of gene knockout. VEGFA is very important in the role of neurons, because they also require vascular supply, and abolishing the expression of VEGFA in neural progenitor cells will lead to defects in cerebral vascularization and neuronal apoptosis¹⁶. Anti-VEGFA therapy can be used to treat patients with poor angiogenesis and vascular leakage in cancer and ocular diseases, but can also lead to inhibition of neurogenesis and neuroprotection¹⁷. VEGFA can be used to treat patients suffering from neurodegenerative diseases and neurological diseases, and can also increase vascular permeability, thereby terminating the blood-brain barrier and increasing inflammatory cell infiltration. Although this project has identified that HIF-1 α gene can target and regulate VEGFA to promote tumor cell proliferation, migration, invasion, neovascularization and lymph node metastasis, the mediation mechanism is not fully understood, and further research is needed.

Early experimental results have shown that the effect of HIF-1 α may affect the expression of VEGFA, thereby affecting some tumor behaviors¹⁸⁻²⁰. The results of this experiment finally show that HIF-1 α can target the regulatory gene VEGFA to promote tumor cell proliferation, migration, invasion, new blood vessel




Figure 4. The results of cell invasion test. The result of normal control (NC) group is equivalent to that of healthy people. **A:** NC group. **B:** hypoxia group-1 (Hy-1) group. **C:** hypoxia group-2 (Hy-2) group. **D:** Hy-1 + si-HIF-1 α group. **E:** Hy-2 + si-HIF-1 α group.




Figure 5. The Western blot analysis results of protein hypoxia-inducible factor 1 α (HIF-1 α), vascular endothelial growth factor A (VEGFA) and glyceraldehyde phosphate dehydrogenase (GAPDH). The data of normal control (NC) group are all equivalent to that of healthy people. **A:** original gel electrophoresis image. **B-D:** the ratio of protein HIF-1 α , VEGFA and GAPDH expression compared to NC group. The symbol * means $p < 0.05$, ** means $p < 0.01$ (compared to the NC group).

formation, and lymph node metastasis, which provide new references and alternative strategies for the diagnosis and treatment of bladder cancer in the future.

Funding

The authors declare this work was funded by the Jiangsu Medical Innovation Team (CXTDA-2017-48);

National Natural Science Foundation of China (81774089); Jiangsu Province, natural science research projects (17KJB360001, 18KJB180007).

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

References

1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014;507:315-22.
2. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*. 2013;63:234-41.
3. Zhan Y, Du L, Wang L, Jiang X, Zhang S, Li J, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. *Mol Cancer*. 2018;17:142.
4. Loras A, Trasserra M, Sanjuan-Herráez D, Martínez-Bisbal MC, Castell JV, Quintás G, et al. Bladder cancer recurrence surveillance by urine metabolomics analysis. *Sci Rep*. 2018;8:9172.
5. Vaupel P, Multhoff G. Fatal alliance of hypoxia/HIF-1 α -driven microenvironmental traits promoting cancer progression. *Adv Exp Med Biol*. 2020;1232:169-76.
6. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. *Curr Opin Genet Dev*. 2010;20:51-6.
7. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1 α -mediated aerobic glycolysis as metabolic basis for trained immunity. *Science*. 2014;345:1250684.
8. Nagao A, Kobayashi M, Koyasu S, Chow CC, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. *Int J Mol Sci*. 2019;20:238.
9. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. *J Intern Med*. 2013;273:114-27.
10. Chen X, Zeng K, Xu M, Liu X, Hu X, Xu T, et al. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2. *Cell Death Dis*. 2019;10:131.
11. Cao W, Zhao Y, Wang L, Huang X. Circ0001429 regulates progression of bladder cancer through binding miR-205-5p and promoting VEGFA expression. *Cancer Biomark*. 2019;25:101-13.
12. Wu YP, Lin YZ, Lin MY, Lin TT, Chen SH, Wei Y, et al. Risk factors for bladder cancer recurrence survival in patients with upper-tract urothelial carcinoma. *Tumori*. 2018;104:451-8.
13. Zhang S, Zhong G, He W, Yu H, Huang J, Lin T. lncRNA up-regulated in nonmuscle invasive bladder cancer facilitates tumor growth and acts as a negative prognostic factor of recurrence. *J Urol*. 2016;196:1270-8.
14. Robrahn L, Jiao L, Cramer T. Barrier integrity and chronic inflammation mediated by HIF-1 impact on intestinal tumorigenesis. *Cancer Lett*. 2020;490:186-92.
15. Xiao B, Wang S, Yang G, Sun X, Zhao S, Lin L, et al. HIF-1 α contributes to hypoxia adaptation of the naked mole rat. *Oncotarget*. 2017;8:109941-51.
16. Kolshus E, Ryan KM, Blackshields G, Smyth P, Sheils O, McLoughlin DM. Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression. *Acta Psychiatr Scand*. 2017;136:594-606.
17. Han N, Xu H, Yu N, Wu Y, Yu L. MiR-203a-3p inhibits retinal angiogenesis and alleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR) rat model via targeting VEGFA and HIF-1 α . *Clin Exp Pharmacol Physiol*. 2020;47:85-94.
18. Hunter BA, Eustace A, Irlam JJ, Valentine HR, Denley H, Oguejiofor KK, et al. Expression of hypoxia-inducible factor-1 α predicts benefit from hypoxia modification in invasive bladder cancer. *Br J Cancer*. 2014;111:437-43.
19. Radford A, Hinley J, Pilborough A, Southgate J, Subramaniam R. Hypoxic changes to the urothelium as a bystander of end-stage bladder disease. *J Pediatr Urol*. 2019;15:158.e1-158.e110.
20. Tickoo SK, Milowsky MI, Dhar N, Dudas ME, Gallagher DJ, Al-Ahmadie H, et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. *BJU Int*. 2011;107:844-9.